WO2024028896A1 - A topical spray based on beta caryophylene for the management of pain and inflammation - Google Patents
A topical spray based on beta caryophylene for the management of pain and inflammation Download PDFInfo
- Publication number
- WO2024028896A1 WO2024028896A1 PCT/IN2023/050741 IN2023050741W WO2024028896A1 WO 2024028896 A1 WO2024028896 A1 WO 2024028896A1 IN 2023050741 W IN2023050741 W IN 2023050741W WO 2024028896 A1 WO2024028896 A1 WO 2024028896A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- mixture
- caryophyllene
- minutes
- pain
- Prior art date
Links
- 208000002193 Pain Diseases 0.000 title claims abstract description 65
- 229940041677 topical spray Drugs 0.000 title claims abstract description 62
- 230000036407 pain Effects 0.000 title claims abstract description 55
- 230000004054 inflammatory process Effects 0.000 title claims abstract description 25
- NPNUFJAVOOONJE-ZIAGYGMSSA-N trans-caryophyllene Natural products C1CC(C)=CCCC(=C)[C@H]2CC(C)(C)[C@@H]21 NPNUFJAVOOONJE-ZIAGYGMSSA-N 0.000 title claims abstract description 25
- 206010061218 Inflammation Diseases 0.000 title claims abstract description 20
- NPNUFJAVOOONJE-UHFFFAOYSA-N beta-cariophyllene Natural products C1CC(C)=CCCC(=C)C2CC(C)(C)C21 NPNUFJAVOOONJE-UHFFFAOYSA-N 0.000 title claims abstract description 15
- NPNUFJAVOOONJE-GFUGXAQUSA-N (-)-beta-caryophyllene Chemical group C1CC(/C)=C/CCC(=C)[C@H]2CC(C)(C)[C@@H]21 NPNUFJAVOOONJE-GFUGXAQUSA-N 0.000 title description 2
- 239000000203 mixture Substances 0.000 claims abstract description 149
- 229960000686 benzalkonium chloride Drugs 0.000 claims abstract description 17
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims abstract description 17
- 239000003380 propellant Substances 0.000 claims abstract description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 16
- 208000035475 disorder Diseases 0.000 claims abstract description 16
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 14
- NPNUFJAVOOONJE-UONOGXRCSA-N caryophyllene Natural products C1CC(C)=CCCC(=C)[C@@H]2CC(C)(C)[C@@H]21 NPNUFJAVOOONJE-UONOGXRCSA-N 0.000 claims abstract description 11
- 229940117948 caryophyllene Drugs 0.000 claims description 53
- 239000007921 spray Substances 0.000 claims description 42
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 27
- 230000000202 analgesic effect Effects 0.000 claims description 25
- 239000003921 oil Substances 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 17
- 239000002904 solvent Substances 0.000 claims description 16
- 244000223014 Syzygium aromaticum Species 0.000 claims description 13
- 235000016639 Syzygium aromaticum Nutrition 0.000 claims description 13
- 238000003756 stirring Methods 0.000 claims description 13
- 240000007707 Mentha arvensis Species 0.000 claims description 8
- 235000018978 Mentha arvensis Nutrition 0.000 claims description 8
- 235000016278 Mentha canadensis Nutrition 0.000 claims description 8
- 239000013078 crystal Substances 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 6
- 229920000053 polysorbate 80 Polymers 0.000 claims description 6
- NVEQFIOZRFFVFW-UHFFFAOYSA-N 9-epi-beta-caryophyllene oxide Natural products C=C1CCC2OC2(C)CCC2C(C)(C)CC21 NVEQFIOZRFFVFW-UHFFFAOYSA-N 0.000 claims description 5
- 244000223760 Cinnamomum zeylanicum Species 0.000 claims description 5
- FAMPSKZZVDUYOS-UHFFFAOYSA-N alpha-Caryophyllene Natural products CC1=CCC(C)(C)C=CCC(C)=CCC1 FAMPSKZZVDUYOS-UHFFFAOYSA-N 0.000 claims description 5
- 239000003205 fragrance Substances 0.000 claims description 5
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 claims description 4
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 claims description 4
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 claims description 4
- 239000003974 emollient agent Substances 0.000 claims description 4
- 239000003995 emulsifying agent Substances 0.000 claims description 4
- NNPPMTNAJDCUHE-UHFFFAOYSA-N isobutane Chemical compound CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 claims description 4
- 239000003755 preservative agent Substances 0.000 claims description 4
- 239000003381 stabilizer Substances 0.000 claims description 4
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims description 3
- 235000004310 Cinnamomum zeylanicum Nutrition 0.000 claims description 3
- 240000002548 Gaultheria fragrantissima Species 0.000 claims description 3
- 235000001703 Gaultheria fragrantissima Nutrition 0.000 claims description 3
- 235000005097 Pinus roxburghii Nutrition 0.000 claims description 3
- 244000057845 Pinus roxburghii Species 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 239000003961 penetration enhancing agent Substances 0.000 claims description 3
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 3
- 229940068968 polysorbate 80 Drugs 0.000 claims description 3
- 230000002335 preservative effect Effects 0.000 claims description 3
- 235000002567 Capsicum annuum Nutrition 0.000 claims description 2
- 240000004160 Capsicum annuum Species 0.000 claims description 2
- 239000001273 butane Substances 0.000 claims description 2
- 235000017663 capsaicin Nutrition 0.000 claims description 2
- 229960002504 capsaicin Drugs 0.000 claims description 2
- 239000001511 capsicum annuum Substances 0.000 claims description 2
- 238000007865 diluting Methods 0.000 claims description 2
- 239000000294 eucalyptus globulus labille leaf/twig oil Substances 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 239000001282 iso-butane Substances 0.000 claims description 2
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 claims description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 claims description 2
- 235000019198 oils Nutrition 0.000 claims description 2
- 239000001294 propane Substances 0.000 claims description 2
- 239000002023 wood Substances 0.000 claims description 2
- 239000003209 petroleum derivative Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 12
- 206010039897 Sedation Diseases 0.000 abstract description 7
- 230000036280 sedation Effects 0.000 abstract description 7
- 238000011282 treatment Methods 0.000 abstract description 7
- 208000037976 chronic inflammation Diseases 0.000 abstract description 4
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 238000010521 absorption reaction Methods 0.000 abstract description 3
- 208000037893 chronic inflammatory disorder Diseases 0.000 abstract description 2
- -1 bicyclic sesquiterpene compound Chemical class 0.000 description 20
- 150000001875 compounds Chemical class 0.000 description 8
- 102100036214 Cannabinoid receptor 2 Human genes 0.000 description 7
- 229930003827 cannabinoid Natural products 0.000 description 7
- 239000003557 cannabinoid Substances 0.000 description 7
- 241000196324 Embryophyta Species 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 208000005298 acute pain Diseases 0.000 description 6
- 229960001259 diclofenac Drugs 0.000 description 6
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 5
- 229940065144 cannabinoids Drugs 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 102000009135 CB2 Cannabinoid Receptor Human genes 0.000 description 4
- 108010073376 CB2 Cannabinoid Receptor Proteins 0.000 description 4
- 208000000094 Chronic Pain Diseases 0.000 description 4
- 241000759176 Copaifera langsdorffii Species 0.000 description 4
- 201000004624 Dermatitis Diseases 0.000 description 4
- 244000025221 Humulus lupulus Species 0.000 description 4
- 235000008694 Humulus lupulus Nutrition 0.000 description 4
- 244000178870 Lavandula angustifolia Species 0.000 description 4
- 235000010663 Lavandula angustifolia Nutrition 0.000 description 4
- 241001529734 Ocimum Species 0.000 description 4
- 240000007673 Origanum vulgare Species 0.000 description 4
- 244000203593 Piper nigrum Species 0.000 description 4
- 244000178231 Rosmarinus officinalis Species 0.000 description 4
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 4
- 229960001193 diclofenac sodium Drugs 0.000 description 4
- 229960004242 dronabinol Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
- 229930014626 natural product Natural products 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 4
- JABYJIQOLGWMQW-UHFFFAOYSA-N undec-4-ene Chemical compound CCCCCCC=CCCC JABYJIQOLGWMQW-UHFFFAOYSA-N 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 208000006820 Arthralgia Diseases 0.000 description 3
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 3
- 244000025254 Cannabis sativa Species 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 235000008184 Piper nigrum Nutrition 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 208000038016 acute inflammation Diseases 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- 150000002430 hydrocarbons Chemical class 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- 102000018208 Cannabinoid Receptor Human genes 0.000 description 2
- 108050007331 Cannabinoid receptor Proteins 0.000 description 2
- 241000218236 Cannabis Species 0.000 description 2
- 235000008697 Cannabis sativa Nutrition 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 2
- 206010012335 Dependence Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 235000013628 Lantana involucrata Nutrition 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 235000006677 Monarda citriodora ssp. austromontana Nutrition 0.000 description 2
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 235000011205 Ocimum Nutrition 0.000 description 2
- 235000010676 Ocimum basilicum Nutrition 0.000 description 2
- 235000010677 Origanum vulgare Nutrition 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000003044 adaptive effect Effects 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 235000013614 black pepper Nutrition 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000001407 cinnamomum spp. Substances 0.000 description 2
- 235000017803 cinnamon Nutrition 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 2
- SWXVUIWOUIDPGS-UHFFFAOYSA-N diacetone alcohol Chemical compound CC(=O)CC(C)(C)O SWXVUIWOUIDPGS-UHFFFAOYSA-N 0.000 description 2
- RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 description 2
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 2
- 230000000763 evoking effect Effects 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000021472 generally recognized as safe Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 239000001102 lavandula vera Substances 0.000 description 2
- 235000018219 lavender Nutrition 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- 208000004296 neuralgia Diseases 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 210000000929 nociceptor Anatomy 0.000 description 2
- 108091008700 nociceptors Proteins 0.000 description 2
- 229940005483 opioid analgesics Drugs 0.000 description 2
- 210000002856 peripheral neuron Anatomy 0.000 description 2
- 235000015639 rosmarinus officinalis Nutrition 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 235000019615 sensations Nutrition 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 230000037384 skin absorption Effects 0.000 description 2
- 231100000274 skin absorption Toxicity 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 235000013599 spices Nutrition 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 150000003505 terpenes Chemical class 0.000 description 2
- 235000007586 terpenes Nutrition 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 229940042585 tocopherol acetate Drugs 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- FAMPSKZZVDUYOS-HRGUGZIWSA-N (1E,4E,8E)-alpha-humulene Chemical compound C\C1=C/CC(C)(C)\C=C\C\C(C)=C\CC1 FAMPSKZZVDUYOS-HRGUGZIWSA-N 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 1
- IDQBJILTOGBZCR-UHFFFAOYSA-N 1-butoxypropan-1-ol Chemical compound CCCCOC(O)CC IDQBJILTOGBZCR-UHFFFAOYSA-N 0.000 description 1
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 1
- LHENQXAPVKABON-UHFFFAOYSA-N 1-methoxypropan-1-ol Chemical compound CCC(O)OC LHENQXAPVKABON-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 1
- RWKSBJVOQGKDFZ-UHFFFAOYSA-N 16-methylheptadecyl 2-hydroxypropanoate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)C(C)O RWKSBJVOQGKDFZ-UHFFFAOYSA-N 0.000 description 1
- POAOYUHQDCAZBD-UHFFFAOYSA-N 2-butoxyethanol Chemical compound CCCCOCCO POAOYUHQDCAZBD-UHFFFAOYSA-N 0.000 description 1
- MFKRHJVUCZRDTF-UHFFFAOYSA-N 3-methoxy-3-methylbutan-1-ol Chemical compound COC(C)(C)CCO MFKRHJVUCZRDTF-UHFFFAOYSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- BACWTVIXOCGZHC-UHFFFAOYSA-N 5-butyl-5-ethyloxan-2-one Chemical compound CCCCC1(CC)CCC(=O)OC1 BACWTVIXOCGZHC-UHFFFAOYSA-N 0.000 description 1
- JTAXUBKTCAOMTN-UHFFFAOYSA-N Abietinol Natural products CC(C)C1=CC2C=CC3C(C)(CO)CCCC3(C)C2CC1 JTAXUBKTCAOMTN-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010003036 Application site dermatitis Diseases 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- BRTJBNHSYGCSQI-UHFFFAOYSA-N C1=CC=CC=2C3=CC=CC=C3N(C1=2)C1=CC=C(C=C1)P(C1=CC=CC=C1)C1=CC=C(C=C1)N1C2=CC=CC=C2C=2C=CC=CC1=2 Chemical compound C1=CC=CC=2C3=CC=CC=C3N(C1=2)C1=CC=C(C=C1)P(C1=CC=CC=C1)C1=CC=C(C=C1)N1C2=CC=CC=C2C=2C=CC=CC1=2 BRTJBNHSYGCSQI-UHFFFAOYSA-N 0.000 description 1
- 102000009132 CB1 Cannabinoid Receptor Human genes 0.000 description 1
- 108010073366 CB1 Cannabinoid Receptor Proteins 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical group CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- 244000166124 Eucalyptus globulus Species 0.000 description 1
- 235000004692 Eucalyptus globulus Nutrition 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 206010065390 Inflammatory pain Diseases 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000000450 Pelvic Pain Diseases 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 208000008765 Sciatica Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 244000045719 Syzygium Species 0.000 description 1
- 235000012096 Syzygium samarangense Nutrition 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- ZPVGIKNDGJGLCO-VGAMQAOUSA-N [(2s,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)O[C@@]1([C@]2(CO)[C@H]([C@H](O)[C@@H](CO)O2)O)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O ZPVGIKNDGJGLCO-VGAMQAOUSA-N 0.000 description 1
- GQRUHVMVWNKUFW-LWYYNNOASA-N abieta-7,13-dien-18-ol Chemical compound OC[C@]1(C)CCC[C@]2(C)[C@@H](CCC(C(C)C)=C3)C3=CC[C@H]21 GQRUHVMVWNKUFW-LWYYNNOASA-N 0.000 description 1
- 229930001565 abietol Natural products 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000004479 aerosol dispenser Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 150000008051 alkyl sulfates Chemical class 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000003217 anti-cancerogenic effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 208000019804 backache Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- SKKTUOZKZKCGTB-UHFFFAOYSA-N butyl carbamate Chemical compound CCCCOC(N)=O SKKTUOZKZKCGTB-UHFFFAOYSA-N 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 229940067596 butylparaben Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000003375 cannabimimetic effect Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 150000003323 caryophyllene derivatives Chemical class 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- SOROIESOUPGGFO-UHFFFAOYSA-N diazolidinylurea Chemical compound OCNC(=O)N(CO)C1N(CO)C(=O)N(CO)C1=O SOROIESOUPGGFO-UHFFFAOYSA-N 0.000 description 1
- 229960001083 diazolidinylurea Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 229940120503 dihydroxyacetone Drugs 0.000 description 1
- PKPOVTYZGGYDIJ-UHFFFAOYSA-N dioctyl carbonate Chemical compound CCCCCCCCOC(=O)OCCCCCCCC PKPOVTYZGGYDIJ-UHFFFAOYSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- DLAHAXOYRFRPFQ-UHFFFAOYSA-N dodecyl benzoate Chemical compound CCCCCCCCCCCCOC(=O)C1=CC=CC=C1 DLAHAXOYRFRPFQ-UHFFFAOYSA-N 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 230000005496 eutectics Effects 0.000 description 1
- 239000006277 exogenous ligand Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940049654 glyceryl behenate Drugs 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 239000002608 ionic liquid Substances 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000009191 jumping Effects 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 239000003915 liquefied petroleum gas Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 208000012280 low backache Diseases 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-M oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC([O-])=O ZQPPMHVWECSIRJ-KTKRTIGZSA-M 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 description 1
- LLHKCFNBLRBOGN-UHFFFAOYSA-N propylene glycol methyl ether acetate Chemical compound COCC(C)OC(C)=O LLHKCFNBLRBOGN-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001823 pruritic effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 235000019633 pungent taste Nutrition 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 229930004725 sesquiterpene Natural products 0.000 description 1
- 150000004354 sesquiterpene derivatives Chemical class 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
- 239000006208 topical dosage form Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
- A61K36/15—Pinaceae (Pine family), e.g. pine or cedar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
Definitions
- the present invention generally relates to pharmaceutical sciences. Specifically, the present invention is related to a topical spray composition comprising isolated P-caryophyllene, benzalkonium chloride, propellant, pharmaceutically acceptable excipients, and optionally an additional active component for the management of pain, inflammation, and other pain related disorders. Also, the present invention provides a method for producing the same and uses thereof.
- Beta-Caryophyllene chemically represented as trans-(lR, 9S)-8-Methylene- 4,l l,l l-trimethylbicyclo-7.2.0 undec-4-ene or lR-(lR4E.9S)-4,l l,l l-trimethyl-8-methylene- bicyclo7.2.0 undec-4-ene) is a natural bicyclic sesquiterpene compound found in spice blends, citrus flavors, Soaps, detergents, creams and lotions, and also in a variety of food products and beverages.
- trans-caryophyllene (E)-BCP) mixed with small amounts of its isomers, (Z)-P-caryophyllene (iso-caryophyllene) and a-humulene (a-caryophyllene), as well as its oxidation derivative — P-caryophyllene oxide (BCPO).
- BCP mainly stands for (E)-BCP or the natural mixture of BCP isomers.
- P-caryophyllene is the first known dietary cannabinoid, a common component of food that has GRAS (Generally Recognized as Safe) status and approved by FDA as well as by the European Food Safety Authority (EFSA) with identification number FL no: 01.007 for food use.
- GRAS Generally Recognized as Safe
- EFSA European Food Safety Authority
- BCP is a colorless to slightly buttery liquid with a light clove-like fragrance. It is soluble in ether and ethanol, insoluble in water.
- the chemical structure of P-caryophyllene is as follows:
- BCP is one of the major active components of essential oils derived from large number of spice and food plants. According to Essential Oil Database, BCP as a plant volatile compound is commonly found in basil (Ocimum spp.), cinnamon (Cinnamomum spp.), black pepper (Piper nigrum L.), cloves (Syzygium aromaticum), cannabis (Cannabis sativa L.), lavender (Lavandula angustifolia), oregano (Origanum vulgare L.), rosemary (Rosmarinus officinalis), hops (Humulus lupulus), and copaiba (Copaifera langsdorffii).
- P-caryophyllene has several biological effects including anti-inflammatory, anticarcinogenic, antimicrobial, antioxidative, and analgesic activities.
- P-caryophyllene is the primary sesquiterpene contributing to the spiciness of black pepper.
- P-caryophyllene belongs to a class of cannabinoids (CBs), specifically phytocannabinoids (pCBs), which were identified as plant derivatives of Cannabis sativa L.
- Natural and synthetic cannabinoids activate the cannabinoid receptors CB1 and CB2, however P- caryophyllene activates exclusively CB2 and exhibits no affinity to CB1.
- Klaudyna et. al. [Cancer Medicine 2016; 5( 10):3007-3017] in a study reported through quantitative radioligand binding experiments that P-caryophyllene displays insensibly higher biding affinity to CB2 and do not bind to CB 1. This implies that P-caryophyllene action is devoid of psychoactive side effects associated with CB 1 activation and suggests its potential use in medicine.
- Pain is a subjective sensation, evoked by various internal and external stimuli. It is an unpleasant feeling, which arises from sensitization of nociceptors — peripheral neurons responding to pain stimuli. Pain is classified as acute or chronic, according to its duration. Short-lived pain, generally associated with tissue damage or painful stimuli (e.g. the pain associated with a slight burn, a cut etc.), is defined "acute pain", and has an adaptive value as it warns us of the presence and location of a lesion and allows us to correct the behavior which causes it or contributes to it.
- Pain which persists beyond the time necessary for resolution of an acute condition is defined as "chronic pain”. Pain is a serious social burden; it affects quality of life and leads to economic loss for patients as well as health services. It has been estimated that 20% of adults suffer from pain globally and around 10% of population worldwide suffers from long lasting pain [Goldberg and McGee BMC Public Health 2011, 11:770].
- various substances are used, generally of a synthetic nature such as non-steroid anti-inflammatory drugs, opioids, etc., which induce analgesia, i.e., reduction in the sensation of pain.
- the treatments may be necessary for long periods, sometimes even for life. This leads to overuse of synthetic or semisynthetic pain killers such as opioids or nonsteroidal anti-inflammatory drugs (NSAIDs). Prolonged consumption of these medicines may cause serious side effects leading to health complications as well as drug tolerance for analgesic effect and addiction.
- synthetic drugs natural products with strong analgesic activities and low side effects are sought.
- cannabinoid receptors have been extensively studied as mediators of analgesia and thus potential targets for treatment of acute and neuropathic pain and inflammation. Activation of those receptors by endo- and exogenous ligands may inhibit pain responses, therefore CBs are considered as substances with high analgesic activities.
- THC tetrahydrocannabinol
- P-caryophyllene has potential as an efficient natural analgesic without any side effects like psychoactivity, dependence and sedation.
- P-caryophyllene based analgesic compositions have been reported.
- US20080280996 provides a composition comprising caryophyllenes including P-caryophyllene for the treatment of inflammatory conditions and inflammatory pain.
- AU2020412501 provides a composition comprising terpenes including P-caryophyllene for the treatment of pain and anxiety.
- P-caryophyllene has extremely low solubility in biological fluids leading to low bioavailability of P-caryophyllene and insufficient analgesic effect. This limits exploitation of this readily available, natural, and safe analgesic to its fullest potential.
- the present invention provides a topical spray composition for the management of pain, inflammation, and related disorders.
- the said composition comprises 2% w/w to 98% w/w of an isolated P-caryophyllene, 0.01% w/w to 3.5% w/w of benzalkonium chloride, 10% w/w to 70% w/w of a propellant, 30% w/w to 70% w/w of at least one excipient, and optionally 0.05% w/w to 40% w/w of an additional active component.
- the said composition is in form of a topical spray which can be sprayed on the skin to obtain relief from pain and inflammation within 2 minutes and the analgesic effect imparted by the said topical spray composition sustains for about 18 hours.
- the topical spray composition provided herein has enhanced absorption on the skin.
- the present invention also provides simple process for the preparation of said topical spray composition, method for the management of pain, inflammation, and related disorders by spraying said composition on the skin of a subject, and uses of said composition in the management of pain, inflammation, and related disorders.
- the topical spray composition provided herein is natural, safe, economic, and easy to prepare on industrial scale.
- the topical spray composition provided herein has analgesic effect better than the standard diclofenac -based analgesic sprays and has no side-effects like psycho-activity, dependence, and sedation.
- Figure 1 illustrates onset time through evaluation of response latency of the composition disclosed herein (20% w/w of P-caryophyllene, TruMove Spray) in comparison with standard pain relief spray based on diclofenac (1% w/w of Diclofenac sodium).
- Figure 2 illustrates duration of analgesic effect through evaluation of % protection against acute pain imparted by the composition disclosed herein (20% w/w of P-caryophyllene, TruMove Spray) in comparison with standard pain relief spray based on diclofenac ( 1 % w/w of Diclofenac sodium).
- Figure 3 illustrates Visual Analogue Scale (VAS), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and McGill pain scores from baseline to Post study in both the groups by the composition disclosed herein (20% w/w of P-caryophyllene, TruMove Spray) in comparison with standard pain relief spray based on diclofenac (1% w/w of Diclofenac sodium).
- VAS Visual Analogue Scale
- WOMAC Osteoarthritis Index
- TruMove or “TruMove spray” used herein refers to a series of test products based on the topical spray composition provided herein.
- a topical spray composition for the management of pain, inflammation, and related disorders comprising: a therapeutically effective amount of an isolated P-caryophyllene; a pharmaceutically acceptable amount of a benzalkonium chloride; a pharmaceutically acceptable amount of a propellant; a pharmaceutically acceptable excipient; and optionally an additional active component.
- P-caryophyllene or “beta-caryophyllene” or “BCP” or “beta caryophyllene” used herein refers to a compound represented by the following formula:
- isolated P-caryophyllene refers to P-caryophyllene available commercially as mixture of oils, P-caryophyllene extracted from natural plants by conventional methods, or P- caryophyllene prepared by synthetic routes.
- the topical spray composition provided herein comprises a therapeutically effective amount of isolated P-caryophyllene.
- the topical spray composition provided herein comprises about 2% w/w to 98% w/w of isolated P-caryophyllene.
- the isolated P-caryophyllene present in the topical spray composition is in form of oil comprising about 70% w/w to 100% w/w of P-caryophyllene.
- the isolated P-caryophyllene present in the topical spray composition is in form of oil extracted from a group of plants comprising basil ⁇ Ocimum spp.), cinnamon ⁇ Cinnamomum spp.), black pepper Piper nigrum L.), cloves ⁇ Syzygium aromaticuni), cannabis Cannabis sativa L.), lavender ⁇ Lavandula angustifolia), oregano ⁇ Origanum vulgare L.), rosemary ⁇ Rosmarinus officinalis), hops ⁇ Humulus lupulus), and copaiba ⁇ Copaifera langsdorffii).
- the isolated P-caryophyllene is extracted from cloves.
- the isolated P-caryophyllene is extracted from clove leaves.
- therapeutically effective amount refers to the amount of the active ingredient in a composition which halts or reduces the progress of the condition being treated or which otherwise completely or partly cures or acts palliatively on the condition.
- the therapeutically effective amount of isolated P-caryophyllene in the topical spray composition disclosed herein is in a range of about 20mg to 980mg.
- the therapeutically effective amount of isolated P- caryophyllene is in a range of about lOmg to 70mg.
- the term “about” used herein refers to the referenced numeric indication plus or minus 10% of that referenced numeric indication.
- Benzalkonium Chloride or “BAC” used herein refers to a compound represented by the following formula: wherein n is equal to 8, 10, 12, 14, 16 and 18.
- the topical spray composition provided herein comprises a pharmaceutically acceptable amount of benzalkonium chloride.
- the topical spray composition provided herein comprises benzalkonium chloride in a concentration range of 0.01% w/w to 3.5% w/w of the composition.
- the topical spray composition provided herein has enhanced skin absorption due to incorporation of benzalkonium chloride.
- the enhanced absorption of the composition disclosed herein is increasing the bioavailability of P-caryophyllene and enabling sufficient analgesic effect in highly safe manner through activation of only CB2 receptor.
- the topical spray composition provided herein comprises a pharmaceutically acceptable excipient.
- pharmaceutically acceptable excipient refers to a compound or ingredient that is compatible with the other ingredients in a pharmaceutical composition and not injurious to an intended subject when administered in normal or therapeutically effective amounts.
- an “intended subject” includes animals and/or humans.
- patient and “subject” may be used interchangeably.
- the topical spray composition provided herein comprises an excipient in a concentration range of 30% w/w to 70% w/w of the composition.
- the topical spray composition provided herein comprises an excipient selected from a group of commonly used excipients in topical spray compositions comprising emulsifier, preservative, penetration enhancer, emollient, stabilizing agent, solvent, fragrance, and a combination thereof.
- the topical spray composition provided herein comprises a pharmaceutically acceptable emulsifier selected from a group of commonly used emulsifiers comprising non-ionic surface active agent e.g., polyoxyethylene alkyl ether, polyoxyethylene fatty acid ester, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene hydrogenated castor oil, sucrose fatty acid ester, glycerin fatty acid ester, sorbitan fatty acid ester, anionic surface active agent e.g., alkyl phosphoric acid ester, alkyl sulfate ester, soap, polyoxyethylene alkyl phosphate acid ester, polyoxyethylene alkyl sulfate, and a combination thereof.
- non-ionic surface active agent e.g., polyoxyethylene alkyl ether, polyoxyethylene fatty acid ester, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene hydrogenated castor oil, sucrose fatty acid ester, glycerin fatty acid este
- the topical spray composition provided herein comprises a pharmaceutically acceptable stabilizing agent selected from a group of commonly used stabilizing agents comprising sodium alginate, sodium carboxymethyl cellulose (CMC), guar gum, locust bean gum, carrageenan, gelatin, pectin, and a combination thereof.
- a pharmaceutically acceptable stabilizing agent selected from a group of commonly used stabilizing agents comprising sodium alginate, sodium carboxymethyl cellulose (CMC), guar gum, locust bean gum, carrageenan, gelatin, pectin, and a combination thereof.
- the topical spray composition provided herein comprises a pharmaceutically acceptable preservative selected from a group of commonly used preservatives comprising benzalkonium chloride, diazolidinyl urea; iodopropnyl butylcarbamate; vitamin E (alpha- tocopherol) and its derivatives including vitamin E acetate (alpha-tocopherol acetate); vitamin C (ascorbic acid); butylated hydroxytoluene (BHT); butylated hydroxyanisole (BHA); esters of p-hydroxy benzoic acid such as methylparaben (p-hydroxybenzoic acid methyl ester), ethylparaben (p- hydroxybenzoic acid ethyl ester), propylparaben (p-hydroxybenzoic acid n- propyl ester), and butylparaben (p-hydroxybenzoic acid n-butyl ester), and a combination thereof.
- a pharmaceutically acceptable preservative selected
- the topical spray composition provided herein comprises a pharmaceutically acceptable emollient selected from a group of commonly used emollients comprising oils, waxes, natural oils derived from plants, silicone oil, polyunsaturated fatty acid, lanoline, dicaprylic ether, isopropyl palmitate, dicaprylyl carbonate, C12-C15 alkyl benzoate, isopropyl isononate, sucrose palmitate, sucrose oleate, isostearyl lactate, glyceryl behenate, triglycerol-4 isostearate, lauryl pirrolidone carboxylic acid, pantenyl triacetate, and a combination thereof.
- a pharmaceutically acceptable emollient selected from a group of commonly used emollients comprising oils, waxes, natural oils derived from plants, silicone oil, polyunsaturated fatty acid, lanoline, dicaprylic ether, isopropyl palmitate, dicap
- the topical spray composition provided herein comprises a pharmaceutically acceptable solvent selected from a group of commonly used solvents comprising ketones such as acetone, diacetone alcohol, dihydroxyacetone, ethyl butyl Valero lactone, methyl ethyl ketone etc., aliphatic or aromatic alcohols such as methanol, ethanol, propanol, benzyl alcohol, butyl alcohol, t-butyl alcohol, butylene glycol, diethylene glycol, abietyl alcohol, propylene carbonate, hexyl alcohol, isopropanol etc., glycol ethers such as butoxy ethanol, butoxypropanol, 3-methyl-3-methoxy-butanol, methoxypropanol etc., esters such as butyl acetate, ethyl acetate, 1 -methoxy-2-propanol acetate etc., benzoates, siloxanes, cyclic silicones, and
- the topical spray composition provided herein comprises ethanol as solvent.
- the topical spray composition provided herein comprises a pharmaceutically acceptable fragrance or flavouring agent selected from a group of commonly used fragrances or flavouring agents selected from a group comprising natural oils, synthetic oils, alcohols, aldehydes, ketones, esters, lactones, hydrocarbons, and a combination thereof.
- the topical spray composition provided herein comprises a pharmaceutically acceptable penetration enhancer selected from a group comprising pyrrolidone, alcohol especially, ester, water, ester sulfoxide (such as dimethyl sulfoxide) and their derivatives, hydrocarbon, terpene and derivatives, benzalkonium chloride, azone and its analogs, amide (including urea and its derivatives), fatty acids, surfactants, oleodendrimers, ionic liquids, and deep eutectic solvents, and a combination thereof.
- a pharmaceutically acceptable penetration enhancer selected from a group comprising pyrrolidone, alcohol especially, ester, water, ester sulfoxide (such as dimethyl sulfoxide) and their derivatives, hydrocarbon, terpene and derivatives, benzalkonium chloride, azone and its analogs, amide (including urea and its derivatives), fatty acids, surfactants, oleodendrimers, ionic
- the topical spray composition provided herein comprises a propellant.
- the propellant used in the topical spray provided herein can be any pharmaceutically acceptable propellant which provides a suitable pressure within an aerosol dispenser, preferably a pressure in range of 20 pounds per square inch gauge (psig) to 130 pounds per square inch gauge (psig).
- the topical spray composition provided herein comprises a propellant in a concentration range of 10% w/w to 70% w/w of the composition.
- the topical spray composition provided herein comprises a propellant selected from a group comprising nitrogen, carbon dioxide, hydrocarbons, and a combination thereof.
- the topical spray composition provided herein comprises a propellant selected from a group comprising LPG, propane, butane, isobutane, dimethylether, hydrofluorocarbons, hydrochlorofluorocarbons, nitrogen, air, and a combination thereof.
- the topical spray composition provided herein comprises an optional additional active component.
- active component refers to a component which has some already known biological activity.
- the said component can be an individual biologically active compound or a mixture of biologically active compounds.
- the biologically active compounds may or may not have analgesic activity.
- the said component can be of natural origin, a natural identical of a natural compound, or a semi-synthetic derivative of a natural compound.
- the topical spray composition provided herein comprises optionally an additional active component in a concentration range of 0.05% w/w to 40% w/w of the composition.
- the topical spray composition provided herein comprises optionally an additional active component selected from a group comprising Gaultheria fragrantissima leaf oil, Mentha arvensis crystals, Syzygium aromaticum flower bud oil, Syzygium aromaticum (Lavang), Standaradized clove extract (containing P Caryophyllene), Pinus roxburghii heart wood oil, Eucalyptus globulus leaf oil, Cinnamomum zeylanicum dried inner bark oil, capsicum annuum, capsaicin, and a combination thereof.
- an additional active component selected from a group comprising Gaultheria fragrantissima leaf oil, Mentha arvensis crystals, Syzygium aromaticum flower bud oil, Syzygium aromaticum (Lavang), Standaradized clove extract (containing P Caryophyllene), Pinus roxburghii heart wood oil, Eucalyptus globulus leaf oil, Cinnamomum zeylanicum dried inner bark oil
- the topical spray composition provided herein is applied topically on the skin once a day to four times a day to a patient or subject.
- the topical spray composition provided herein has an onset time between 2 minutes to 15 minutes.
- onset time refers to the period of time between the topical application of the topical dosage form comprising the composition of the present invention and the release of the active ingredient thereof.
- the topical spray composition provided herein has analgesic effect for a duration of 17 hours to 18 hours from the onset time.
- the topical spray composition provided herein is used for the management of pain, inflammation, and related disorders.
- pain or inflammation refers to a subjective sensation, evoked by various internal and external stimuli. It is an unpleasant feeling, which arises from sensitization of nociceptors, the peripheral neurons responding to pain stimuli.
- the term "pain” or “inflammation” includes acute pain or inflammation as well as chronic pain or inflammation.
- the short-lived acute pain or inflammation is generally associated with tissue damage or painful stimuli (e.g., the pain associated with a slight burn, a cut etc.).
- Acute pain or inflammation has an adaptive value as it warns us of the presence and location of a lesion and allows us to correct the behavior which causes it or contributes to it.
- pain or inflammation which persists beyond the time necessary for resolution of an acute condition is defined as chronic pain or inflammation.
- the topical spray composition provided herein is useful in the management of pain in medical conditions selected from a group comprising arthralgia, backache, neuralgia, ischialgia, fibromyalgia, musculo-skeletal pain, pelvic pain, and related disorders.
- the topical spray composition provided herein is useful in the management of pain in medical conditions selected from a group comprising atopic dermatitis, contact dermatitis, allergic dermatitis, pruritic dermatitis, solar (UVB -induced) dermatitis, chemical-induced dermatitis, bacterial and viral skin inflammation, acne, psoriasis, and related disorders.
- a process for the preparation of topical spray composition comprises steps of, preparing a mixture of Mentha arvensis crystals and a solvent in a mixer by stirring Mentha arvensis crystals and a solvent at a speed in range of 10 rpm to 500 rpm for a duration of 15 minutes to 25 minutes to obtain a first mixture; adding isolated P-caryophyllene, at least one excipient, and at least one additional active component into the first mixture and stirring the first mixture at a speed in range of 10 rpm to 500 rpm for a duration of 10 minutes to 15 minutes to obtain a second mixture; adding isopropyl myristate and polysorbate 80 (Tween 80) into the second mixture and stirring the second mixture at a speed in range of 10 rpm to 500 rpm for a duration of 5 minutes to 10 minutes to obtain a third mixture; preparing a solution of benzalkonium chloride in a solvent, adding the solution into
- the topical spray composition provided herein may be filled in an aluminium aerosol container without a propellant to obtain a topical spray.
- ethanol is used as solvent.
- a method for the management of pain, inflammation, and related disorders by applying on the skin of a subject the topical spray composition provided by the present invention.
- a topical spray composition provided by the present invention in the management of pain, inflammation, and related disorders.
- the topical spray composition provided herein is natural, safe, economic, and easy to prepare on industrial scale.
- the topical spray composition provided herein has analgesic effect better than diclofenac based topical analgesic sprays. Due to presence of natural analgesic P-caryophyllene as major component, the topical spray composition provided herein is extremely safe and free from adverse reactions like application site dermatitis which is generally experienced by patients in long term usage of diclofenac based topical sprays. The safety associated with the topical spray composition provided herein will lead to better patient compliance.
- the topical spray composition provided herein has no side-effects like psycho-activity, dependence, sedation etc., and can be advantageously used as a safe alternative to natural cannabinoid analgesic e.g., THC which activates both CB1 and CB2 receptors to trigger undesirable psychoactivity.
- cannabinoid analgesic e.g., THC which activates both CB1 and CB2 receptors to trigger undesirable psychoactivity.
- a mixture of Mentha arvensis crystals and ethanol is prepared by stirring Mentha arvensis crystals and ethanol at a speed in range of 10 rpm to 500 rpm for a duration of 15 minutes to 20 minutes.
- Lavang Synzygium aromaticum
- Gandhapura Gaultheria fragrantissima
- Lavang Synzygium aromaticum
- Fl. Bud Oil Lavang (Syzygium aromaticum)
- Sarala Pieri
- Ht.Wd. Oil Nilgiri (Eucalyptus globulus) Lf. Oil
- Dalchini Cinnamomum zeylanicum
- Oil are added and stirred at a speed in range of 10 rpm to 500 rpm for a duration of 10 minutes to 15 minutes. Thereafter, isopropyl myristate and polysorbate 80 (Tween 80) are added into the mixture so obtained followed by stirring at a speed in range of 10 rpm to 500 rpm for a duration of 5 minutes to 10 minutes.
- An ethanolic solution of benzalkonium chloride is prepared in a separate container by stirring ethanol and benzalkonium chloride at a speed in range of 10 rpm to 500 rpm for a duration of 5 minutes to 10 minutes.
- the ethanolic solution of benzalkonium chloride so prepared is then added into the mixture in main manufacturing vessel and stirred for 5 minutes at a speed in range of 10 rpm to 500 rpm.
- the mixture so obtained is then diluted with ethanol, stirred, and filtered to obtain a concentrate.
- the concentrate is then filled inside a spray bottle with a propellant to obtain 20% TruMove spray 01 of composition provided in Table- 1 below.
- Table-2 Composition of 20% TruMove spray 01 1.3. Preparation of 20% TruMove spray 03
- Table-3 Composition of 20% TruMove spray 03
- a topical spray comprising not less than 20% w/w of beta-caryophyllene is evaluated for stability at 40 °C ⁇ 2 °C /75 ⁇ 5 % RH and 30 °C ⁇ 2 °C / 75 ⁇ 5 % RH for initial, 3 months’ and 6 months’ .
- the result of the study is provided in Table-4 below:
- a comparative study is performed to evaluate the analgesic efficiency of the composition disclosed herein in form of a spray comprising 20% w/w of P-caryophyllene (TruMove Spray) in comparison with a standard pain relief spray comprising 1 % w/w of Diclofenac sodium.
- Table-5 WOMAC score
- Table-6 McGill Pain score comparison.
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention provides a topical spray composition based on the phytocannabinoid β- caryophyllene (BCP) for the management of pain, inflammation, and related disorders. The composition comprises β-caryophyllene in isolated form, benzalkonium chloride, propellant, pharmaceutically acceptable excipient, and optionally an additional active component. The topical spray composition has enhanced absorption on skin and imparts effective protection against pain, inflammation, and related disorders. The composition is specifically useful in the treatment of chronic inflammatory disorders as it is free from undesirable side-effects like psycho-activity, dependence, and sedation. The present invention also provides a method for producing the same and uses thereof.
Description
A TOPICAL SPRAY BASED ON BETA CARYOPHYLENE FOR THE
MANAGEMENT OF PAIN AND INFLAMMATION
FIELD OF THE INVENTION
The present invention generally relates to pharmaceutical sciences. Specifically, the present invention is related to a topical spray composition comprising isolated P-caryophyllene, benzalkonium chloride, propellant, pharmaceutically acceptable excipients, and optionally an additional active component for the management of pain, inflammation, and other pain related disorders. Also, the present invention provides a method for producing the same and uses thereof.
BACKGROUND OF THE INVENTION
Beta-Caryophyllene (P-Caryophyllene) chemically represented as trans-(lR, 9S)-8-Methylene- 4,l l,l l-trimethylbicyclo-7.2.0 undec-4-ene or lR-(lR4E.9S)-4,l l,l l-trimethyl-8-methylene- bicyclo7.2.0 undec-4-ene) is a natural bicyclic sesquiterpene compound found in spice blends, citrus flavors, Soaps, detergents, creams and lotions, and also in a variety of food products and beverages.
In nature, it mainly occurs as trans-caryophyllene ((E)-BCP) mixed with small amounts of its isomers, (Z)-P-caryophyllene (iso-caryophyllene) and a-humulene (a-caryophyllene), as well as its oxidation derivative — P-caryophyllene oxide (BCPO). In scientific literature, BCP mainly stands for (E)-BCP or the natural mixture of BCP isomers. P-caryophyllene is the first known dietary cannabinoid, a common component of food that has GRAS (Generally Recognized as Safe) status and approved by FDA as well as by the European Food Safety Authority (EFSA) with identification number FL no: 01.007 for food use.
BCP is a colorless to slightly buttery liquid with a light clove-like fragrance. It is soluble in ether and ethanol, insoluble in water. The chemical structure of P-caryophyllene is as follows:
BCP is one of the major active components of essential oils derived from large number of spice and food plants. According to Essential Oil Database, BCP as a plant volatile compound is commonly found in basil (Ocimum spp.), cinnamon (Cinnamomum spp.), black pepper (Piper nigrum L.), cloves (Syzygium aromaticum), cannabis (Cannabis sativa L.), lavender (Lavandula angustifolia), oregano (Origanum vulgare L.), rosemary (Rosmarinus officinalis), hops (Humulus lupulus), and copaiba (Copaifera langsdorffii).
P-caryophyllene has several biological effects including anti-inflammatory, anticarcinogenic, antimicrobial, antioxidative, and analgesic activities. P-caryophyllene is the primary sesquiterpene contributing to the spiciness of black pepper. P-caryophyllene belongs to a class of cannabinoids (CBs), specifically phytocannabinoids (pCBs), which were identified as plant derivatives of Cannabis sativa L.
Natural and synthetic cannabinoids activate the cannabinoid receptors CB1 and CB2, however P- caryophyllene activates exclusively CB2 and exhibits no affinity to CB1. Klaudyna et. al. [Cancer Medicine 2016; 5( 10):3007-3017] in a study reported through quantitative radioligand binding experiments that P-caryophyllene displays insensibly higher biding affinity to CB2 and do not bind to CB 1. This implies that P-caryophyllene action is devoid of psychoactive side effects associated with CB 1 activation and suggests its potential use in medicine.
This selective CB2 activation properties of P-caryophyllene suggests that P-caryophyllene has potential as natural analgesic through significant cannabimimetic anti-inflammatory effects.
Further, Clayton et al. [Pain 96(2002) 253-260] in a study reported that activation of CB2 receptor alone is sufficient to produce anti-inflammatory and analgesic effect. Activation of CB 1 receptor is likely to produce unwanted CNS side effects as these receptors have a wide distribution in the brain and are associated with psychoactivity, dependence and sedation. There is no such reported side effect associated with CB2 agonists. CB2 receptors are expressed exclusively in peripheral tissues and are not associated with any side effects. CB2 agonists therefore have the potential to provide safe and effective treatment of chronic inflammatory disorders.
Pain is a subjective sensation, evoked by various internal and external stimuli. It is an unpleasant feeling, which arises from sensitization of nociceptors — peripheral neurons responding to pain stimuli. Pain is classified as acute or chronic, according to its duration. Short-lived pain, generally associated with tissue damage or painful stimuli (e.g. the pain associated with a slight burn, a cut etc.), is defined "acute pain", and has an adaptive value as it warns us of the presence and location of a lesion and allows us to correct the behavior which causes it or contributes to it.
On the other hand, pain which persists beyond the time necessary for resolution of an acute condition is defined as "chronic pain". Pain is a serious social burden; it affects quality of life and leads to economic loss for patients as well as health services. It has been estimated that 20% of adults suffer from pain globally and around 10% of population worldwide suffers from long lasting pain [Goldberg and McGee BMC Public Health 2011, 11:770].
In the treatment of pain, in particular chronic pain, various substances are used, generally of a synthetic nature such as non-steroid anti-inflammatory drugs, opioids, etc., which induce analgesia, i.e., reduction in the sensation of pain. The treatments may be necessary for long periods, sometimes even for life. This leads to overuse of synthetic or semisynthetic pain killers such as opioids or nonsteroidal anti-inflammatory drugs (NSAIDs). Prolonged consumption of these medicines may cause serious side effects leading to health complications as well as drug tolerance for analgesic effect and addiction.
To decrease use of synthetic drugs, natural products with strong analgesic activities and low side effects are sought. Because of these cannabinoid receptors have been extensively studied as mediators of analgesia and thus potential targets for treatment of acute and neuropathic pain and inflammation. Activation of those receptors by endo- and exogenous ligands may inhibit pain responses, therefore CBs are considered as substances with high analgesic activities. Highly studied natural product i.e., cannabinoids from cannabis majorly contains tetrahydrocannabinol (THC), which is approved for the supportive care of several medical conditions in Austria, Belgium, Canada, and several states of the United States. THC mediates through cannabinoid receptors CB 1 and CB2. Therefore, long term usage can lead to psychoactivity, dependence and sedation.
In view of the above findings, it is evident that P-caryophyllene has potential as an efficient natural analgesic without any side effects like psychoactivity, dependence and sedation. P-caryophyllene based analgesic compositions have been reported.
US20080280996 provides a composition comprising caryophyllenes including P-caryophyllene for the treatment of inflammatory conditions and inflammatory pain.
AU2020412501 provides a composition comprising terpenes including P-caryophyllene for the treatment of pain and anxiety.
However, P-caryophyllene has extremely low solubility in biological fluids leading to low bioavailability of P-caryophyllene and insufficient analgesic effect. This limits exploitation of this readily available, natural, and safe analgesic to its fullest potential.
Therefore, need exists for the development of a P-caryophyllene -based analgesic topical spray composition which has enhanced skin absorption and bioavailability of P-caryophyllene for faster and efficient pain relief without any side effects like sedation, addiction, and psychoactivity.
SUMMARY OF THE INVENTION
Accordingly, the present invention provides a topical spray composition for the management of pain, inflammation, and related disorders. The said composition comprises 2% w/w to 98% w/w of an isolated P-caryophyllene, 0.01% w/w to 3.5% w/w of benzalkonium chloride, 10% w/w to 70% w/w of a propellant, 30% w/w to 70% w/w of at least one excipient, and optionally 0.05% w/w to 40% w/w of an additional active component.
The said composition is in form of a topical spray which can be sprayed on the skin to obtain relief from pain and inflammation within 2 minutes and the analgesic effect imparted by the said topical spray composition sustains for about 18 hours. The topical spray composition provided herein has enhanced absorption on the skin.
The present invention also provides simple process for the preparation of said topical spray composition, method for the management of pain, inflammation, and related disorders by spraying said composition on the skin of a subject, and uses of said composition in the management of pain, inflammation, and related disorders.
The topical spray composition provided herein is natural, safe, economic, and easy to prepare on industrial scale.
The topical spray composition provided herein has analgesic effect better than the standard diclofenac -based analgesic sprays and has no side-effects like psycho-activity, dependence, and sedation.
BRIEF DESCRIPTION OF DRAWINGS
The accompanying drawings illustrate some of the embodiments of the present invention and, together with the descriptions, serve to explain the invention. These drawings have been provided by way of illustration and not by way of limitation. The components in the drawings are not necessarily drawn to scale, emphasis instead being placed upon clearly illustrating the principles of the aspects of the embodiments.
Figure 1 illustrates onset time through evaluation of response latency of the composition disclosed herein (20% w/w of P-caryophyllene, TruMove Spray) in comparison with standard pain relief spray based on diclofenac (1% w/w of Diclofenac sodium).
Figure 2 illustrates duration of analgesic effect through evaluation of % protection against acute pain imparted by the composition disclosed herein (20% w/w of P-caryophyllene, TruMove Spray) in comparison with standard pain relief spray based on diclofenac ( 1 % w/w of Diclofenac sodium).
Figure 3 illustrates Visual Analogue Scale (VAS), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and McGill pain scores from baseline to Post study in both the groups by the composition disclosed herein (20% w/w of P-caryophyllene, TruMove Spray) in comparison with standard pain relief spray based on diclofenac (1% w/w of Diclofenac sodium).
DETAILED DESCRIPTION OF THE INVENTION
The invention will now be described in detail in connection with certain preferred and optional embodiments, so that various aspects thereof may be more fully interpreted and comprehended. However, any skilled person or artisan will appreciate the extent to which such embodiments could be generalized in practice.
Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context dictates otherwise, between the upper and lower limit of that range and any other stated or intervening value in that stated range is encompassed within the invention. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges also encompassed within the invention, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the invention.
Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present invention, the preferred methods and materials are now described. All publications mentioned herein are incorporated herein by reference to disclose and describe the methods and/or materials in connection with which the publications are cited.
It must be noted that as used herein and in the appended claims, the singular forms "a", "and", and "the" include plural referents unless the context dictates otherwise. Thus, for example, reference to "a compound" includes a plurality of such compounds, and reference to "the step" includes reference to one or more steps and equivalents thereof known to those skilled in the art, and so forth.
The publications discussed herein are provided solely for their availability to the applicant before the filing date of the present application. Nothing herein is to be construed as an admission that the present invention is not entitled to antedate such publication by the prior invention. Further, the dates of publication provided may be different from the actual publication dates which may need to be independently confirmed.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the disclosure, the preferred method, and materials are now described.
The term “TruMove” or “TruMove spray” used herein refers to a series of test products based on the topical spray composition provided herein.
In one aspect of the present invention, there is provided a topical spray composition for the management of pain, inflammation, and related disorders comprising: a therapeutically effective amount of an isolated P-caryophyllene; a pharmaceutically acceptable amount of a benzalkonium chloride; a pharmaceutically acceptable amount of a propellant; a pharmaceutically acceptable excipient; and optionally an additional active component.
The term “P-caryophyllene" or “beta-caryophyllene” or “BCP” or “beta caryophyllene” used herein refers to a compound represented by the following formula:
and chemically defined as trans-(lR, 9S)-8-Methylene-4,l l,l l-trimethylbicyclo-7.2.0 undec-4- ene or 1R-(1R4E.9S)-4,11,1 l-trimethyl-8-methylene-bicyclo7.2.0 undec-4-ene).
The term “isolated P-caryophyllene” used herein refers to P-caryophyllene available commercially as mixture of oils, P-caryophyllene extracted from natural plants by conventional methods, or P- caryophyllene prepared by synthetic routes.
The topical spray composition provided herein comprises a therapeutically effective amount of isolated P-caryophyllene.
In an embodiment of the present invention, the topical spray composition provided herein comprises about 2% w/w to 98% w/w of isolated P-caryophyllene.
In an embodiment of the present invention, the isolated P-caryophyllene present in the topical spray composition is in form of oil comprising about 70% w/w to 100% w/w of P-caryophyllene.
In an embodiment of the present invention, the isolated P-caryophyllene present in the topical spray composition is in form of oil extracted from a group of plants comprising basil {Ocimum spp.), cinnamon {Cinnamomum spp.), black pepper Piper nigrum L.), cloves {Syzygium aromaticuni), cannabis Cannabis sativa L.), lavender {Lavandula angustifolia), oregano {Origanum vulgare L.), rosemary {Rosmarinus officinalis), hops {Humulus lupulus), and copaiba {Copaifera langsdorffii).
In an embodiment of the present invention, the isolated P-caryophyllene is extracted from cloves.
In an embodiment of the present invention, the isolated P-caryophyllene is extracted from clove leaves. The term "therapeutically effective amount" as used herein refers to the amount of the active ingredient in a composition which halts or reduces the progress of the condition being treated or which otherwise completely or partly cures or acts palliatively on the condition.
The therapeutically effective amount of isolated P-caryophyllene in the topical spray composition disclosed herein is in a range of about 20mg to 980mg.
In an embodiment of the present invention, the therapeutically effective amount of isolated P- caryophyllene is in a range of about lOmg to 70mg. The term “about” used herein refers to the referenced numeric indication plus or minus 10% of that referenced numeric indication.
The term “Benzalkonium Chloride” or “BAC” used herein refers to a compound represented by the following formula:
wherein n is equal to 8, 10, 12, 14, 16 and 18. The topical spray composition provided herein comprises a pharmaceutically acceptable amount of benzalkonium chloride.
In an embodiment of the present invention, the topical spray composition provided herein comprises benzalkonium chloride in a concentration range of 0.01% w/w to 3.5% w/w of the composition.
The topical spray composition provided herein has enhanced skin absorption due to incorporation of benzalkonium chloride. The enhanced absorption of the composition disclosed herein is increasing the bioavailability of P-caryophyllene and enabling sufficient analgesic effect in highly safe manner through activation of only CB2 receptor.
The topical spray composition provided herein comprises a pharmaceutically acceptable excipient.
The term “pharmaceutically acceptable excipient” used herein refers to a compound or ingredient that is compatible with the other ingredients in a pharmaceutical composition and not injurious to an intended subject when administered in normal or therapeutically effective amounts. As used herein, an “intended subject” includes animals and/or humans. The terms “patient” and “subject” may be used interchangeably.
In an embodiment of the present invention, the topical spray composition provided herein comprises an excipient in a concentration range of 30% w/w to 70% w/w of the composition.
In an embodiment of the present invention, the topical spray composition provided herein comprises an excipient selected from a group of commonly used excipients in topical spray compositions comprising emulsifier, preservative, penetration enhancer, emollient, stabilizing agent, solvent, fragrance, and a combination thereof.
In an embodiment of the present invention, the topical spray composition provided herein comprises a pharmaceutically acceptable emulsifier selected from a group of commonly used emulsifiers comprising non-ionic surface active agent e.g., polyoxyethylene alkyl ether, polyoxyethylene fatty acid ester, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene hydrogenated castor oil, sucrose fatty acid ester, glycerin fatty acid ester, sorbitan fatty acid ester,
anionic surface active agent e.g., alkyl phosphoric acid ester, alkyl sulfate ester, soap, polyoxyethylene alkyl phosphate acid ester, polyoxyethylene alkyl sulfate, and a combination thereof.
In an embodiment of the present invention, the topical spray composition provided herein comprises a pharmaceutically acceptable stabilizing agent selected from a group of commonly used stabilizing agents comprising sodium alginate, sodium carboxymethyl cellulose (CMC), guar gum, locust bean gum, carrageenan, gelatin, pectin, and a combination thereof.
In an embodiment of the present invention, the topical spray composition provided herein comprises a pharmaceutically acceptable preservative selected from a group of commonly used preservatives comprising benzalkonium chloride, diazolidinyl urea; iodopropnyl butylcarbamate; vitamin E (alpha- tocopherol) and its derivatives including vitamin E acetate (alpha-tocopherol acetate); vitamin C (ascorbic acid); butylated hydroxytoluene (BHT); butylated hydroxyanisole (BHA); esters of p-hydroxy benzoic acid such as methylparaben (p-hydroxybenzoic acid methyl ester), ethylparaben (p- hydroxybenzoic acid ethyl ester), propylparaben (p-hydroxybenzoic acid n- propyl ester), and butylparaben (p-hydroxybenzoic acid n-butyl ester), and a combination thereof.
In an embodiment of the present invention, the topical spray composition provided herein comprises a pharmaceutically acceptable emollient selected from a group of commonly used emollients comprising oils, waxes, natural oils derived from plants, silicone oil, polyunsaturated fatty acid, lanoline, dicaprylic ether, isopropyl palmitate, dicaprylyl carbonate, C12-C15 alkyl benzoate, isopropyl isononate, sucrose palmitate, sucrose oleate, isostearyl lactate, glyceryl behenate, triglycerol-4 isostearate, lauryl pirrolidone carboxylic acid, pantenyl triacetate, and a combination thereof.
In an embodiment of the present invention, the topical spray composition provided herein comprises a pharmaceutically acceptable solvent selected from a group of commonly used solvents comprising ketones such as acetone, diacetone alcohol, dihydroxyacetone, ethyl butyl Valero lactone, methyl ethyl ketone etc., aliphatic or aromatic alcohols such as methanol, ethanol,
propanol, benzyl alcohol, butyl alcohol, t-butyl alcohol, butylene glycol, diethylene glycol, abietyl alcohol, propylene carbonate, hexyl alcohol, isopropanol etc., glycol ethers such as butoxy ethanol, butoxypropanol, 3-methyl-3-methoxy-butanol, methoxypropanol etc., esters such as butyl acetate, ethyl acetate, 1 -methoxy-2-propanol acetate etc., benzoates, siloxanes, cyclic silicones, and a combination thereof.
In an embodiment of the present invention, the topical spray composition provided herein comprises ethanol as solvent.
In an embodiment of the present invention, the topical spray composition provided herein comprises a pharmaceutically acceptable fragrance or flavouring agent selected from a group of commonly used fragrances or flavouring agents selected from a group comprising natural oils, synthetic oils, alcohols, aldehydes, ketones, esters, lactones, hydrocarbons, and a combination thereof.
In an embodiment of the present invention, the topical spray composition provided herein comprises a pharmaceutically acceptable penetration enhancer selected from a group comprising pyrrolidone, alcohol especially, ester, water, ester sulfoxide (such as dimethyl sulfoxide) and their derivatives, hydrocarbon, terpene and derivatives, benzalkonium chloride, azone and its analogs, amide (including urea and its derivatives), fatty acids, surfactants, oleodendrimers, ionic liquids, and deep eutectic solvents, and a combination thereof.
The topical spray composition provided herein comprises a propellant.
The propellant used in the topical spray provided herein can be any pharmaceutically acceptable propellant which provides a suitable pressure within an aerosol dispenser, preferably a pressure in range of 20 pounds per square inch gauge (psig) to 130 pounds per square inch gauge (psig).
In an embodiment of the present invention, the topical spray composition provided herein comprises a propellant in a concentration range of 10% w/w to 70% w/w of the composition.
In an embodiment of the present invention, the topical spray composition provided herein comprises a propellant selected from a group comprising nitrogen, carbon dioxide, hydrocarbons, and a combination thereof.
In an embodiment of the present invention, the topical spray composition provided herein comprises a propellant selected from a group comprising LPG, propane, butane, isobutane, dimethylether, hydrofluorocarbons, hydrochlorofluorocarbons, nitrogen, air, and a combination thereof.
The topical spray composition provided herein comprises an optional additional active component.
The term “active component” used herein refers to a component which has some already known biological activity. The said component can be an individual biologically active compound or a mixture of biologically active compounds. The biologically active compounds may or may not have analgesic activity. The said component can be of natural origin, a natural identical of a natural compound, or a semi-synthetic derivative of a natural compound.
In an embodiment of the present invention, the topical spray composition provided herein comprises optionally an additional active component in a concentration range of 0.05% w/w to 40% w/w of the composition.
In an embodiment of the present invention, the topical spray composition provided herein comprises optionally an additional active component selected from a group comprising Gaultheria fragrantissima leaf oil, Mentha arvensis crystals, Syzygium aromaticum flower bud oil, Syzygium aromaticum (Lavang), Standaradized clove extract (containing P Caryophyllene), Pinus roxburghii heart wood oil, Eucalyptus globulus leaf oil, Cinnamomum zeylanicum dried inner bark oil, capsicum annuum, capsaicin, and a combination thereof.
The topical spray composition provided herein is applied topically on the skin once a day to four times a day to a patient or subject.
The topical spray composition provided herein has an onset time between 2 minutes to 15 minutes.
The term "onset time" as used herein refers to the period of time between the topical application of the topical dosage form comprising the composition of the present invention and the release of the active ingredient thereof.
The topical spray composition provided herein has analgesic effect for a duration of 17 hours to 18 hours from the onset time.
The topical spray composition provided herein is used for the management of pain, inflammation, and related disorders.
As used herein, the term “pain” or “inflammation" refers to a subjective sensation, evoked by various internal and external stimuli. It is an unpleasant feeling, which arises from sensitization of nociceptors, the peripheral neurons responding to pain stimuli. The term "pain” or “inflammation includes acute pain or inflammation as well as chronic pain or inflammation. The short-lived acute pain or inflammation is generally associated with tissue damage or painful stimuli (e.g., the pain associated with a slight burn, a cut etc.). Acute pain or inflammation has an adaptive value as it warns us of the presence and location of a lesion and allows us to correct the behavior which causes it or contributes to it. On the other hand, pain or inflammation which persists beyond the time necessary for resolution of an acute condition is defined as chronic pain or inflammation.
In an embodiment of the present invention, the topical spray composition provided herein is useful in the management of pain in medical conditions selected from a group comprising arthralgia, backache, neuralgia, ischialgia, fibromyalgia, musculo-skeletal pain, pelvic pain, and related disorders.
In an embodiment of the present invention, the topical spray composition provided herein is useful in the management of pain in medical conditions selected from a group comprising atopic dermatitis, contact dermatitis, allergic dermatitis, pruritic dermatitis, solar (UVB -induced)
dermatitis, chemical-induced dermatitis, bacterial and viral skin inflammation, acne, psoriasis, and related disorders.
In another aspect of the present invention, a process for the preparation of topical spray composition provided herein is disclosed. The said process comprises steps of, preparing a mixture of Mentha arvensis crystals and a solvent in a mixer by stirring Mentha arvensis crystals and a solvent at a speed in range of 10 rpm to 500 rpm for a duration of 15 minutes to 25 minutes to obtain a first mixture; adding isolated P-caryophyllene, at least one excipient, and at least one additional active component into the first mixture and stirring the first mixture at a speed in range of 10 rpm to 500 rpm for a duration of 10 minutes to 15 minutes to obtain a second mixture; adding isopropyl myristate and polysorbate 80 (Tween 80) into the second mixture and stirring the second mixture at a speed in range of 10 rpm to 500 rpm for a duration of 5 minutes to 10 minutes to obtain a third mixture; preparing a solution of benzalkonium chloride in a solvent, adding the solution into the third mixture and stirring the third mixture at a speed in range of 10 rpm to 500 rpm for a duration of 5 minutes to 10 minutes to obtain a fourth mixture; diluting the fourth mixture with solvent and stirring the fourth mixture at a speed in range of 10 rpm to 500 rpm for a duration of 5 minutes to 10 minutes to obtain a fifth mixture; filtering the fifth mixture and filling the fifth mixture in a spray bottle with a propellant to obtain the composition.
The topical spray composition provided herein may be filled in an aluminium aerosol container without a propellant to obtain a topical spray.
In one of the embodiments of the present invention, the process for preparation of topical spray composition disclosed herein, ethanol is used as solvent.
In another aspect of the present invention, there is provided a method for the management of pain, inflammation, and related disorders by applying on the skin of a subject the topical spray composition provided by the present invention.
In another aspect of the present invention, there is provided use of the topical spray composition provided by the present invention in the management of pain, inflammation, and related disorders.
The topical spray composition provided herein is natural, safe, economic, and easy to prepare on industrial scale.
The topical spray composition provided herein has analgesic effect better than diclofenac based topical analgesic sprays. Due to presence of natural analgesic P-caryophyllene as major component, the topical spray composition provided herein is extremely safe and free from adverse reactions like application site dermatitis which is generally experienced by patients in long term usage of diclofenac based topical sprays. The safety associated with the topical spray composition provided herein will lead to better patient compliance.
The topical spray composition provided herein has no side-effects like psycho-activity, dependence, sedation etc., and can be advantageously used as a safe alternative to natural cannabinoid analgesic e.g., THC which activates both CB1 and CB2 receptors to trigger undesirable psychoactivity.
It will be understood that the specification and examples are illustrative but not limitative of the present invention and that other embodiments within the spirit and scope of the present invention will suggest themselves to those skilled in the art. Other embodiments can be practiced that are also within the scope of the present invention. The following examples illustrate the invention, but by no means intended to limit the scope of the claims.
EXAMPLES
EXAMPLE 1: PREPARATION OF ANALGESIC SPRAY FTRUMOVE SPRAY1
1.1. Preparation of 20% TruMove spray 01
In main manufacturing vessel, a mixture of Mentha arvensis crystals and ethanol is prepared by stirring Mentha arvensis crystals and ethanol at a speed in range of 10 rpm to 500 rpm for a duration of 15 minutes to 20 minutes. In the mixture so obtained, Lavang (Syzygium aromaticum),
Gandhapura (Gaultheria fragrantissima) Lf. Oil, Lavang (Syzygium aromaticum) Fl. Bud Oil, Sarala (Pinus roxburghii) Ht.Wd. Oil, Nilgiri (Eucalyptus globulus) Lf. Oil, and Dalchini (Cinnamomum zeylanicum) Dr. Inner Bk. Oil are added and stirred at a speed in range of 10 rpm to 500 rpm for a duration of 10 minutes to 15 minutes. Thereafter, isopropyl myristate and polysorbate 80 (Tween 80) are added into the mixture so obtained followed by stirring at a speed in range of 10 rpm to 500 rpm for a duration of 5 minutes to 10 minutes. An ethanolic solution of benzalkonium chloride is prepared in a separate container by stirring ethanol and benzalkonium chloride at a speed in range of 10 rpm to 500 rpm for a duration of 5 minutes to 10 minutes. The ethanolic solution of benzalkonium chloride so prepared is then added into the mixture in main manufacturing vessel and stirred for 5 minutes at a speed in range of 10 rpm to 500 rpm. The mixture so obtained is then diluted with ethanol, stirred, and filtered to obtain a concentrate. The concentrate is then filled inside a spray bottle with a propellant to obtain 20% TruMove spray 01 of composition provided in Table- 1 below.
1.2.Preparation of 20% TruMove spray 02
20% TruMove spray 02 having composition as provided in Table-2 below is prepared using method detailed in Example 1.1.
20% TruMove spray 03 having composition as provided in Table-3 below is prepared using method detailed in Example 1.1.
EXAMPLE 2: STABILITY STUDIES
A topical spray comprising not less than 20% w/w of beta-caryophyllene is evaluated for stability at 40 °C ± 2 °C /75 ± 5 % RH and 30 °C ± 2 °C / 75 ± 5 % RH for initial, 3 months’ and 6 months’ . The result of the study is provided in Table-4 below:
Table-4: Stability studies results
Conclusion: All the physical and chemical parameters of the spray are found satisfactory and the initial, 3M and 6M stability data at 40 °C ± 2 °C /75 ± 5 % RH, 30 °C ± 2 °C / 75 ± 5 % RH are also found to be satisfactory.
EXAMPLE 3: ANALGESIC EFFECT EVALUATION [TRUMOVE SPRAY]
A comparative study is performed to evaluate the analgesic efficiency of the composition disclosed herein in form of a spray comprising 20% w/w of P-caryophyllene (TruMove Spray) in comparison with a standard pain relief spray comprising 1 % w/w of Diclofenac sodium.
10 healthy male Wistar rats aged between 10 weeks to 12 weeks and weighing between 220 grams to 250 grams are divided into two groups of 5 animals. TruMove spray and the standard pain relief spray were measured in Eppendorf tube by spraying twice and mist volume of both sprays are found to be 500pl. Volume is kept same for all the rats. The response in the form of jumping, withdrawal of the paws or the licking of the paws is observed and response latency recorded by a stopwatch after 0, 30, 60, 90 and 120 mins of drug administration for all groups.
The study shows that there is significantly fast onset of action with Trumove spray (45 seconds) when compared to standard pain relief spray (56 seconds) in all the Musculo-skeletal pain conditions like low back ache, knee joint pain and other joint pain disorders. Also, the onset of pain relief is also fast (2.13 minutes) with Trumove spray when compared to standard pain relief spray (5.27 minutes) as illustrated in Figure- 1. The pain relief action sustains for around 18 hours in Trumove spray and for around 15 hours in standard pain relief spray as illustrated in Figure-2. Further, the VAS, WOMAC and McGill pain scores from baseline to Post study in Trumove spray and standard pain relief spray are comparable as reflected in Table-5 and Table-6 below and illustrated in Figure 3.
The study also reflects that there is significant reduction in the inflammatory biomarkers ESR and Hs-CRP from baseline to Post study in both the groups, but ESR reduction is more prominent in Trumove spray group as reflected in Table-7 and Table-8 below. Table-7: ESR reduction
Conclusion: Pain relief is faster and better in TruMove spray than standard pain relief spray. It will thus be seen that the objects set forth above, among those made apparent from the preceding description, are efficiently attained, and since certain changes may be made in the constructions set forth without departing from the spirit and scope of the invention, it is intended that all matter
contained in the above description shall be interpreted as illustrative and not in a limiting sense. The invention has been described with reference to preferred and alternate embodiments. Modifications and alterations will become apparent to those skilled in the art upon reading and understanding the detailed discussion of the invention provided herein. This invention is intended to include all such modifications and alterations insofar as they come within the scope of the present invention. These and other modifications of the preferred embodiments as well as other embodiments of the invention will be obvious from the disclosure herein, whereby the foregoing descriptive matter is to be interpreted merely as illustrative of the invention and not as a limitation.
Finally, to the extent necessary to understand or complete the disclosure of the present invention, all publications, patents, and patent applications mentioned herein are expressly incorporated by reference therein to the same extent as though each were individually so incorporated.
Claims
1. A topical spray composition for the management of pain, inflammation, and related disorders comprising:
- a therapeutically effective amount of an isolated P-caryophyllene,
- a pharmaceutically acceptable amount of a benzalkonium chloride,
- a pharmaceutically acceptable amount of a propellant,
- a pharmaceutically acceptable excipient, and optionally an additional active component.
2. The composition as claimed in claim 1 , wherein the isolated P-caryophyllene is in form of an oil comprising P-caryophyllene.
3. The composition as claimed in claim 2, wherein the oil comprises 70% w/w to 100% w/w of the P-caryophyllene.
4. The composition as claimed in claim 1, wherein the isolated P-caryophyllene is in a concentration range of 2% w/w to 98% w/w of the composition.
5. The composition as claimed in claim 1, wherein the benzalkonium chloride is in a concentration range of 0.01% w/w to 3.5% w/w of the composition.
6. The composition as claimed in claim 1 , wherein the propellant is in a concentration range of 10% w/w to 70% w/w of the composition.
7. The composition as claimed in claim 1, wherein the excipient is in a concentration range of 30% w/w to 70% w/w of the composition.
8. The composition as claimed in claim 1, wherein the additional active component is in a concentration range of 0.05% w/w to 40% w/w of the composition.
9. The composition as claimed in claim 1, wherein the excipient is selected from a group comprising emulsifier, preservative, emollient, stabilizing agent, solvent, fragrance, penetration enhancer, and a combination thereof.
10. The composition as claimed in claim 1, wherein the additional active component is selected from a group comprising Gaultheria fragrantissima leaf oil, Mentha arvensis crystals, Syzygium aromaticum flower bud oil, Syzygium aromaticum (Lavang), Standaradized clove extract (containing P Caryophyllene), Pinus roxburghii heart wood oil, Eucalyptus globulus leaf oil, Cinnamomum zeylanicum dried inner bark oil, capsicum annuum, capsaicin, and a combination thereof.
11. The composition as claimed in claim 1 , wherein the propellant is selected from a group comprising liquified petroleum gas, propane, butane, isobutane, dimethyl ether, hydrofluorocarbons, hydrochlorofluorocarbons, nitrogen, air, and a combination thereof.
12. The composition as claimed in claim 1, wherein the composition is sprayed on the skin of the patient once a day to four times a day.
13. The composition as claimed in claim 1, wherein the composition has an onset time from 2 minutes to 15 minutes.
14. The composition as claimed in claim 1, wherein the composition has analgesic effect for a duration of 17 hours to 18 hours from the onset time.
15. A process for the preparation of composition as claimed in claim 1, wherein the process comprises step of:
- preparing a mixture of Mentha arvensis crystals and solvent in a mixer by stirring Mentha arvensis crystals and a solvent at a speed in range of 10 rpm to 500 rpm for a duration of 15 minutes to 25 minutes to obtain a first mixture;
- adding isolated P-caryophyllene, at least one excipient, and at least one additional active component into the first mixture and stirring the first mixture at a speed in range of 10 rpm to 500 rpm for a duration of 10 minutes to 15 minutes to obtain a second mixture;
- adding isopropyl myristate and polysorbate 80 (Tween 80) into the second mixture and stirring the second mixture at a speed in range of 10 rpm to 500 rpm for a duration of 5 minutes to 10 minutes to obtain a third mixture;
- preparing a solution of benzalkonium chloride in a solvent, adding the solution into the third mixture and stirring the third mixture at a speed in range of 10 rpm to 500 rpm for a duration of 5 minutes to 10 minutes to obtain a fourth mixture;
- diluting the fourth mixture with a solvent and stirring the fourth mixture at a speed in range of 10 rpm to 500 rpm for a duration of 5 minutes to 10 minutes to obtain a fifth mixture;
- filtering the fifth mixture and filling the fifth mixture in a spray bottle with a propellant to obtain the composition. A process as claimed in claim 15, wherein the solvent is ethanol. A method for the management of pain, inflammation, and related disorders in a subject by applying on the skin of the subject the composition as claimed in claim 1. Use of composition as claimed in claim 1 in the management of pain, inflammation, and related disorders.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN202211043958 | 2022-08-01 | ||
IN202211043958 | 2022-08-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024028896A1 true WO2024028896A1 (en) | 2024-02-08 |
Family
ID=89848611
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IN2023/050741 WO2024028896A1 (en) | 2022-08-01 | 2023-08-01 | A topical spray based on beta caryophylene for the management of pain and inflammation |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024028896A1 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6962691B1 (en) * | 1999-05-20 | 2005-11-08 | U & I Pharmaceuticals Ltd. | Topical spray compositions |
CN108420789A (en) * | 2018-04-16 | 2018-08-21 | 海南皇隆制药股份有限公司 | A kind of benzalkonium chloride externally used solution and preparation method thereof |
US20200030252A1 (en) * | 2018-07-18 | 2020-01-30 | John Enrique Mata | Multifunctional topical cream comprising beta-caryophyllene, essential oils, in a phospholipid and triglyceride base |
-
2023
- 2023-08-01 WO PCT/IN2023/050741 patent/WO2024028896A1/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6962691B1 (en) * | 1999-05-20 | 2005-11-08 | U & I Pharmaceuticals Ltd. | Topical spray compositions |
CN108420789A (en) * | 2018-04-16 | 2018-08-21 | 海南皇隆制药股份有限公司 | A kind of benzalkonium chloride externally used solution and preparation method thereof |
US20200030252A1 (en) * | 2018-07-18 | 2020-01-30 | John Enrique Mata | Multifunctional topical cream comprising beta-caryophyllene, essential oils, in a phospholipid and triglyceride base |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10172897B2 (en) | Enhanced smokable therapeutic cannabis product and method for making same | |
US10206888B2 (en) | Cannabis-based therapeutic product for treatment of chronic pain | |
US20180352848A1 (en) | Smokable cannabis-based product with reduced psychoactive effects | |
WO2018226899A1 (en) | A system and method enhanced cannabinoid effect delivery | |
US20210330638A1 (en) | Nano-penetrative cannabinoid oil blends and compositions and methods of formulation thereof | |
US20180344684A1 (en) | Cannabis-based therapeutic product for treatment of sleep disorders | |
US20190275268A1 (en) | Multi-use cartridge for ingestion of cannabis-based products | |
US9040103B2 (en) | Use of essential oil of oregano and of rosewood, or constituents thereof, in the therapeutic treatment of keratoses | |
US11896575B2 (en) | Transdermal formulation for delivery of hydrophobic compounds and process for the preparation thereof | |
Avoseh et al. | Albizia lebbeck and Albizia zygia volatile oils exhibit anti-nociceptive and anti-inflammatory properties in pain models | |
US20180193304A1 (en) | Phytoterpenoid facilitation of therapeutic onset and efficacy of sublingual cannabinoid administration | |
US20190321306A1 (en) | Cannabis-based therapeutic product for treatment of chronic pain | |
WO2020234650A1 (en) | Pharmaceutical compositions comprising cbd and terpene compositions | |
Adedoyin et al. | Cytotoxicity, antioxidant and antimicrobial activities of essential oil extracted from Euphorbia heterophylla plant | |
Thakur et al. | Therapeutic potential of essential oil-based microemulsions: reviewing state-of-the-art | |
US20220226241A1 (en) | Stable organic cannabinoid oil blend formulations | |
WO2019173242A1 (en) | Enhanced smokable cannabis-based therapeutic product for treatment of sleep disorders and chronic pain and method for making same | |
Qneibi et al. | A Comprehensive Review of Essential Oils and Their Pharmacological Activities in Neurological Disorders: Exploring Neuroprotective Potential | |
WO2024028896A1 (en) | A topical spray based on beta caryophylene for the management of pain and inflammation | |
US11007243B2 (en) | Enzyme-assisted supercritical extraction of nigella sativa seeds | |
US20200094003A1 (en) | Multi-use cartridge for ingestion of cannabis-based products | |
WO2024028897A1 (en) | A topical composition based on beta caryophylene for the management of pain and inflammation | |
US20220304963A1 (en) | Composition having an optimized fatty acid excipient profile | |
Al-Harrasi et al. | Essential Oil Chemistry vs. Aromatherapy | |
Mehta et al. | In Vivo Antidiabetic Activity and GC-MS Analysis of Ethanolic Extracts of Rabdosia Rugosa (Wal. ex Benth.) H. Hara. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23849663 Country of ref document: EP Kind code of ref document: A1 |